Latest Security News

Macarthur Minerals narrowed its loss to $1.82 million for FY26, bolstered by a major new investor and joint venture at its Lake Giles iron ore project in Western Australia.

Sprintex Limited has locked in underwriting agreements covering 8.7 million unexercised options, potentially raising up to A$870,000. The company also agreed to extend a A$1.85 million convertible note maturity by one year, pending shareholder approval.

DevEx Resources has finalised the acquisition of Alligator Energy’s uranium tenements in the Alligator Rivers Uranium Province, expanding its landholding to about 9,200 km² around the historic Nabarlek Mine.

Adherium Limited has obtained a USD 1.65 million short-term unsecured loan from its major shareholder, Trudell Medical, to fund immediate working capital needs while pursuing capital structure adjustments.

ClearVue Technologies is inviting eligible shareholders to participate in a $1 million Share Purchase Plan at a discount, following a $5 million institutional placement. The capital raised will support ERP rollout, R&D, and working capital.

Nimy Resources (ASX: NIM) responds to ASX query following a sharp share price fall, confirming pending assay results from recent sampling but no undisclosed information explaining the trading.

Manuka Resources has secured the final US$4 million tranche of its US$30 million Nebari facility, fueling its push to restart gold production at Mt Boppy and silver output at Wonawinta by September 2026.

Quantum Graphite and Sunlands Pure have cleared a major regulatory hurdle with environmental approvals for their Al Buraimi graphite refinery in Oman, paving the way for large-scale production of high-purity graphite.

Strategic Energy Resources (ASX:SER) has raised $1.5 million through a discounted share placement and a fully underwritten share purchase plan to back a high-impact drilling campaign at its Diamantina Copper-Gold Project in Queensland.

HITIQ Limited has secured $1.4 million through a private placement of 200 million shares at 0.7 cents each, accompanied by options exercisable until 2029. The capital will bolster its balance sheet and back expansion and commercialisation efforts.

BCAL Diagnostics has locked in an additional $4.9 million under its existing convertible note facility alongside a $1.4 million R&D tax offset tranche, reinforcing its funding runway into FY2027 for early cancer detection test development.

Clarity Pharmaceuticals will present compelling data at EANM 2026 demonstrating its 64Cu-SAR-bisPSMA imaging agent’s superior detection of prostate cancer recurrence and promising therapeutic results from 67Cu-SAR-bisPSMA in advanced disease.